Inventor · disambiguated record
Francis X. Muller
Also filed as: MUELLER FRANCIS · MULLER FRANCIS · MULLER FRANCIS X · MULLER FRANCIS XAVIER
17 granted patents·13 pending applications·673 citations·filing 1985–2025
95Inventor score
Top patents by PatentIndex Score
30 records- 0195US11918585B2Formulations of an AXL/MER inhibitorINCYTE CORP·Filed 2021·Granted Mar 5, 2024·4 cites·55 claims
- 0293US5278043ARuthenium-lumazine energy transfer systemsHOFFMANN LA ROCHE·Filed 1991·Granted Jan 11, 1994·159 cites·8 claims
- 0393US4745076ARuthenium complexes useful as carriers for immunologically active materialsHOFFMANN LA ROCHE·Filed 1985·Granted May 17, 1988·104 cites·8 claims
- 0491US5573906ADetection of nucleic acids using a hairpin forming oligonucleotide primer and an energy transfer detection systemHOFFMANN LA ROCHE·Filed 1993·Granted Nov 12, 1996·264 cites·21 claims
- 0590US11241438B2Formulations of an AXL/MER inhibitorINCYTE CORP·Filed 2019·Granted Feb 8, 2022·6 cites·56 claims
- 0690US8052994B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)GLAXOSMITHKLINE LLC·Filed 2009·Granted Nov 8, 2011·9 cites·12 claims
- 0789US8052995B23'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)GLAXOSMITHKLINE LLC·Filed 2009·Granted Nov 8, 2011·8 cites·12 claims
- 0889US8052993B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)GLAXOSMITHKLINE LLC·Filed 2009·Granted Nov 8, 2011·7 cites·12 claims
- 0989US4835438ASource of spin polarized electrons using an emissive micropoint cathodeCOMMISSARIAT ENERGIE ATOMIQUE·Filed 1987·Granted May 30, 1989·61 cites·10 claims
- 1088US8071129B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)MULLER FRANCIS X·Filed 2009·Granted Dec 6, 2011·7 cites·12 claims
- 1188US8062665B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)MULLER FRANCIS X·Filed 2009·Granted Nov 22, 2011·7 cites·12 claims
- 1287US5075447ARuthenium complexes useful as carriers for immunologically active materialsHOFFMANN LA ROCHE·Filed 1988·Granted Dec 24, 1991·26 cites·4 claims
- 1383US12318389B2Formulations of an AXL/MER inhibitorINCYTE CORP·Filed 2024·Granted Jun 3, 2025·0 cites·44 claims
- 1482US2025387401A1Formulations of an axl/mer inhibitorINCYTE CORP·Filed 2025·Application pending·0 cites
- 1579US8828430B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)MULLER FRANCIS X·Filed 2011·Granted Sep 9, 2014·2 cites·12 claims
- 1672US2019209479A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2019·Application pending·0 cites
- 1770US2018338926A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2018·Application pending·0 cites
- 1868US2018117009A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2017·Application pending·0 cites
- 1968US2014341991A13'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)GLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 2067US2017296512A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2017·Application pending·0 cites
- 2166US7875630B2Process salts compositions and useGLAXO GROUP LTD·Filed 2004·Granted Jan 25, 2011·5 cites·37 claims
- 2265US2017112771A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2016·Application pending·0 cites
- 2364US8207191B2Process, salts, composition and useFORTH MICHAEL ANTHONY·Filed 2010·Granted Jun 26, 2012·2 cites·24 claims
- 2464US2010129352A1Novel pharmaceutical compositionMULLER FRANCIS X·Filed 2007·Application pending·0 cites
- 2563US2016199353A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2016·Application pending·0 cites
- 2662US2016031822A13'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)NOVARTIS AG·Filed 2015·Application pending·0 cites
- 2762US2012149749A1Method of treating thrombocytopeniaARNING MICHAEL·Filed 2009·Application pending·0 cites
- 2857US2016143883A1Method of treating thrombocytopeniaKAPSI SHIVAKUMAR G·Filed 2015·Application pending·0 cites
- 2956US2014142155A1Method of treating thrombocytopeniaGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 3031US4639090ALiquid crystal dichroic display with a high brightness contrastCOMMISSARIAT ENERGIE ATOMIQUE·Filed 1985·Granted Jan 27, 1987·2 cites·6 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →